| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| CLOPIDOGREL (has an active metabolite)
| CLOPIDOGREL | BLOOD | ORAL | Cmax 7.7 NANOMOLAR Tmax 0.75 HOUR F 50 PERCENT PPB 98 PERCENT HT 6 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER AT NEUTRAL PH BUT FREELY SOLUBLE AT PH 1 | P2Y PURINOCEPTOR 12 PDB 3ME6 (CRYSTAL STRUCTURE OF CYTOCHROME 2B4 IN COMPLEX WITH THE ANTI-PLATELET DRUG CLOPIDOGREL) LIGAND CODE = CGE (link to the list of PDB complexes) Download experimental 3D coordinates of CGE with added hydrogens | PURINERGIC RECEPTOR P2Y12 ANTAGONIST CHEMBL2001 PURINERGIC RECEPTOR P2Y12 Q9H244 P2Y PURINOCEPTOR 12 HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL NUCLEOTIDE-LIKE RECEPTOR PURINE RECEPTOR | ANSM (in French) | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M CLOPIDOGREL (is an active metabolite)
| CLOPIDOGREL | BLOOD | - | Cmax 64.7 NANOMOLAR (300 MILLIGRAM) Tmax 0.75 HOUR HT 0.5 HOUR | P2Y PURINOCEPTOR 12 | PURINERGIC RECEPTOR P2Y12 ANTAGONIST CHEMBL2001 PURINERGIC RECEPTOR P2Y12 Q9H244 P2Y PURINOCEPTOR 12 HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL NUCLEOTIDE-LIKE RECEPTOR PURINE RECEPTOR | ANSM (in French) | |||
